http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#Head http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#provenance http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#pubinfo http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion http://purl.obolibrary.org/obo/DOID_9538 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9538 http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB06603 http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association http://www.w3.org/2000/01/rdf-schema#label farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival see clinical studies 14 1 farydak a histone deacetylase inhibitor in combination with bortezomib and dexamethasone is indicated for the treatment of patients with multiple myeloma who have received at least 2 prior regimens including bortezomib and an immunomodulatory agent this indication is approved under accelerated approval based on progression free survival continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials 1 http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB06603 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#provenance http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#pubinfo http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig http://purl.org/nanopub/x/hasSignature ejkgAdelRbCwcop+mYWEroyL/NoOAY7gyM1L+ZFCVYs6Rwd0q3O9FNXnkpo3VVcRMm27MPR1G6sunrxvFiJiW+Uf8lA/2E69+oJ5H/TwEFQig80kKP4b0asdnp+L7gJIeO7UZwJLfhJjLHonTahakeB63rj8bPjvaEonSWoXJpM= http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://purl.org/dc/terms/created 2021-06-12T13:26:08.716+02:00 http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RADf4hBIig9ss0hb6oaH9hlG1Ijzv2LLr-wYMwl23ODGo https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs